Ligand Pharmaceuticals (FRA:LGDN) Tax Provision : €-23.2 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Ligand Pharmaceuticals Tax Provision?

Ligand Pharmaceuticals's tax provision for the three months ended in Mar. 2024 was €-25.1 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was €-23.2 Mil.

Ligand Pharmaceuticals Tax Provision Historical Data

The historical data trend for Ligand Pharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Tax Provision Chart

Ligand Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

-150.60

4.36

3.67

-38.92

-9.02

Ligand Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															-11.14	-0.81	1.75	1.00	-25.12

Ligand Pharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-23.2 Mil.

Ligand Pharmaceuticals (FRA:LGDN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (FRA:LGDN) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

LGND:USA

Address

3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121

Website

https://www.ligand.com

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Ligand Pharmaceuticals (FRA:LGDN) Headlines

No Headlines